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Conclusions: GAFCHROMIC® MD-V2-55 radiochromic films has been an 
useful tool to know real dose administration along the breast target 
and to understand some abnormal MOSFET reading. 
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Purpose/Objective: To report outcomes for patients treated with 
salvage surgical resection and intraoperative radiotherapy (IORT) for 
residual or recurrent squamous cell carcinoma (SCC) of the anus after 
primary chemoradiotherapy (CRT). 
Materials and Methods: The prospective radiation oncology 
department IORT database was searched for patients treated with 
surgery and IORT for anal SCC. Thirty-two patients treated between 
1993 and 2012 were identified. All patients had previously received 
primary concurrent CRT and had residual or recurrent disease based 
on clinical findings and/or tissue confirmation. All patients with 
recurrent disease received pre-operative, limited field external beam 
re-irradiation (median dose 30 Gray) and concurrent chemotherapy. 
IORT was utilized due to concern that salvage surgery alone would be 
unlikely to remove all gross and/or microscopic disease. Treatment-
related adverse events were classified according to the National 
Cancer Institute – Common Toxicity Criteria Adverse Events (AEs). 
Overall survival (OS), disease-free survival (DFS), central failure (CF; 
within the IORT field), local-regional failure (LRF; tumor bed or 
draining lymphatics), and distant failure (DF) were estimated using 
the Kaplan-Meier technique. 
Results: Median age at IORT was 53 years (range 34-87). Twenty-six 
patients (81%) were female. Salvage treatment was performed for 
residual disease after CRT (n=9), 1st recurrence after CRT (n=17), or 
2nd recurrence after CRT and salvage abdominal-perineal resection 
(APR, n=6). APR was a component of the multimodality salvage 
attempt in 22 patients. Extent of surgical resection was R0 (negative 
margins, n=16), R1 (microscopic residual, n=13), or R2 (macroscopic 
residual, n=3). IORT was delivered with electron beams (n=31) or high-
dose rate brachytherapy (n=1). Median IORT dose was 12.5 Gray 
(range 7.5 – 20). Median length of hospital stay was 9 days.  
Nine patients (28%) were alive at last follow-up. The median follow-up 
duration was 1.6 years for all patients and 6.3 years for living 
patients. Mortality at 30 days after surgery and IORT was 0%. Fifteen 
patients (47%) experienced a total of 16 grade 3 treatment-related 
AEs. The most common Grade 3 AEs were wound complications (n=6), 
bowel obstruction (n=5), and ureteral obstruction (n=3). There were 
no grade 4 or 5 AEs. The 5-year estimates of OS and DFS were 23% and 
17%, respectively. The 5-year estimates of CF, LRF, and DF were 26%, 
64%, and 48%, respectively. 
Conclusions: In this heavily pre-treated, high-risk patient population, 
aggressive salvage surgery and IORT was associated with long-term 
survival in a small, but significant subset of patients. 
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Purpose/Objective: Breast conserving therapy (BCT) with 
complementary radiotherapy is an effective alternative for 
mastectomy what was confirmed by comparable survivals in 20-years 
observations of randomized trials. Standard procedure after BCT is 
whole breast irradiation with higher dose on tumor bed. The dose 
escalation may be proceeded by brachytherapy, intraoperative 
radiotherapy (IORT) and conformal radiotherapy (3D-CRT) from 
external beams.  
The purpose of this paper was to report four years of IORT during 
breast-conserving surgery (BCS) as a tumor bed boost using high 
energy electrons. 
Materials and Methods: Between May 2008 and November 2012 in 255 
breast cancers treated IORT as a tumor bed boost was applied using 
electron accelerator Mobetron 1000 (IntraOp Medical, Inc.). IORT 
boost (10 Gy) was followed by whole-breast external beam 
radiotherapy (EBRT) – 25 fractions 2.0 Gy each or 15 fractions of 2.7 
Gy each for patients registered in multi-center HIOB trial 
(Hypofractionated Whole-Breast Irradiation preceded by Intra-
Operative Radiotherapy with Electrons as anticipated Boost).  
150 patients were analyzed to evaluate the risk of local failure after 
BCT, IORT boost and EBRT with minimal observation period of 1 year. 
The clinical profile is presented in table. 
After tumor excision, shielding plate was placed on a patient's chest 
wall, underneath breast tissues. Appropriate applicator size and tip 
bevel were chosen to cover whole tumor bed with specified IORT 
margins. Electron energy was precisely chosen to assure homogeneous 
dose distribution and to deliver 10 Gy to the 90% isodose, which 
reaches shielding plate surface, independently of tissue thickness. 




Results: There was no local failure in analyzed group of patients. 
Median age of treated women was 58 years (35 to 77). Patients were 
treated using all available electron beam energies: 6 MeV was used in 
52% cases but also 9 MeV, 4 MeV and 12 MeV (33%, 13% and 2% cases 
respectively) were used for treatment. In 51% cases applicator size 
(which is related to the tumor bedsize) was 5 cm in diameter. The 
smallest used applicator was 4 cm in diameter(27% cases) and the 
largest one was 7 cm (1%). This results in average planning target 
volume - PTV (volume of tissue encompassed by the 90% isodose line) 
of35.31 cc ranging from 12.00 cc to 75.35 cc. In 56% cases no bolus 
was needed; 0.5 cm bolus was used in 83 cases (33%). In all treatment 
procedures aluminium-lead shielding plates were used, 82% of which 
were 0.5 cm thick. The thickness of irradiated breast gland was less 
than 1.5 cm in half of treated cases and between 1.5 cm and 2 cm in 
40%. Breast gland thicker than 2.5 cm was irradiated only in 3% of all 
treated cases (figure). 
 
Conclusions: Intraoperative radiotherapy as a tumor bed boost during 
breast-conserving surgery for breast cancer using high-energy 
electrons from a mobile linear accelerator is proved to be effective 
and perspective treatment procedure. 
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Purpose/Objective: Dose-painting by numbers (DBPN) is gaining 
interest and has the potential to improve tumor local control with 
minimal increase of side effects. Because of the voxel-by-voxel non-
uniform dose prescription in DPBN, usual margin recipes to account 
for geometric and random uncertainties do not apply. Robust 
treatment plans may be achieved by incorporating geometric 
uncertainties during plan optimization. Although powerful, this 
method is not available in most treatment planning systems (TPS) and 
may be time-consuming. Our approach aims at providing a universal 
solution (i.e. TPS independent), by including systematic and random 
geometric uncertainties implicitly in the prescription for DPBN. 
Materials and Methods: We propose here a method that modifies the 
heterogeneous dose prescription DP to ensure robustness of planned 
dose DPlanned against standard deviations of systematic errors Σ and 
random errors σ. The prescription is based in this study on FDG-PET 
images with an escalation from 70 to 86 Gy. The objective was that 
95% of all voxels in the GTVPET received at least 95% of their respective 
prescribed dose even in the presence of geometric errors (Q0.95>95%). 
The prescription DP was modified by a morphological dilation of αΣ 
and a deconvolution by σ (assuming Gaussian distribution). The GTVPET 
was also extended by αΣ, to generate a PTVPET volume. For a 90% 
confidence interval, α=2.5. The planning process was performed on a 
TomoTherapy system such that 95% of the points within PTVPET 
received at least 95% of the modified prescription (Q0.95>95%) and less 
than 5% of the points received more than 105% of the modified 
prescription (quality factors Q0.95 and Q1.05 are derived from the 
cumulative quality volume histograms, the quality factor Q being the 
ratio in each CT voxel between the planned dose and the prescribed 
dose). Robustness was evaluated by translating and blurring DPlanned 
and by comparing the resulting dose with the unmodified dose 
prescription within GTVPET. The methodology was illustrated for two 
head-and-neck tumors treated by helical TomoTherapy.  
Results: For both patients, the TomoTherapy system was capable to 
reproduce modified non-uniform prescriptions with Q0.95>95% and 
Q1.05<5%. Coverage was preserved when systematic and random 
displacements were smaller than αΣ and σ. For larger displacements, 
coverage was degraded. The figure illustrates two examples for one 
patient. In figure (a), no correction of the prescription was 
performed, leading to significant underdosage when geometric errors 
were simulated (down to 62.8% for Q0.95). In figure (b) target coverage 
was preserved even in the presence of geometric errors. 
 
 Conclusions: The method generates treatment plans that are robust 
against geometric uncertainties without the need to handle geometric 
errors in the optimizer of the TPS. The methodology was illustrated 
for head-and-neck but is potentially general for all tumor sites.  
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Purpose/Objective: With ion therapy it is possible to deposit dose 
very precisely, however it is still more sensitive to setup errors, 
interfractional and intrafractional movements than traditional photon 
therapy. When physicists create treatment plans, angle selection is 
solely governed by their intuition and experience. Here, we present a 
model which within seconds can quantify angle quality from CT images 
and structure information for use selection of robust beam 
orientations. 
Materials and Methods: The model creates a 2D grid orthogonal to the 
beam axis at the isocenter. The outer contour of the PTV is projected 
on the grid and the water equivalent path length (WEPL) along the 
particle trajectories are calculated in each pixel of the grid. The 
robustness quality factor (RQF) is determined as 10 minus the mean 
sum of squares of the WEPL pixel-to-pixel variations, i.e. the 
maximum value of 10 represents a perfectly robust plan. A CT scan of 
a tumour of pituitary gland is used for validation of the model. The 
robustness quality factor is then mapped for the entire angular space 
covered by the gantry and couch. Islands of good, intermediate and 
poor angels can be identified, and 15 angles are selected from these 
regions. The 15 angles are then used as validation points for the 
model, in terms of systematic and random errors. The field is 
optimised so the mean dose is 100% in PTV using the treatment 
planning system TRiP. The resulting plan is then shifted with 
systematic offsets along the lateral direction of the beam, and the 
RQF is determined. All recalculations and data analysis are done by 
PyTRiP. For evaluating the plan against systematic setup errors we 
score the V-95% of CTV and evaluate an average setup offset for which 
the 2% of the CTV get less than 95% of prescribed dose. For random 
errors a new dose distribution is generated by adding the dose 
distributions sets with varying offset and weighting them with a 
Gaussian distribution centered at zero offset. In the summed dose 
distribution, the V-95% of CTV is calculated and used directly as a 
quality estimator for the plan. 
Results: For the random error analysis, the V-95% of CTV depends 
slightly on RQF. Values close to 10 (i.e. robust plans) turns out to give 
good coverage, and vice versa. However, angles with intermediate 
RQF show no clear behavior. For systematic errors there a 
straightforward dependency on the RQF can be observed. For a PTV 
with a margin of 4 mm and a robustness quality factor of 5, then the 
mean offset to underdose 2% of the tumour is in the order of 1 mm or 
below. For a quality factor of 9, this is in the order of 2.5 mm. 
 
Conclusions: We have succeeded to create a model which can 
quantify the quality of a chosen beam angle against positioning offset 
errors. The quality is represented by the RQF, and its validity was 
checked against systematic and random errors. We demonstrate that 
RQF is a good representation of the robustness against positioning 
errors. However, tests on additional patient cases may still be 
needed. 
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Purpose/Objective: For patients with metal hip implants AAPM 
taskgroup 63 recommends avoidance of beams that deliver dose to the 
target while first (in part) passing through the implant. Especially for 
patients with bilateral prostheses, this severely limits the search 
space for beam angle selection, generally resulting in less favorable 
dose distributions since primarily only anterior and posterior beams 
can be selected. In this study, we compared this approach with an 
alternative strategy. 
Materials and Methods: All plans were generated fully automatically 
(i.e., no human trial-and-error interactions) using iCycle, our in-house 
developed algorithm for multicriterial optimization of beam angles 
and fluence profiles, allowing objective comparisons of planning 
strategies. For 18 prostate cancer patients (8 with bilateral hip 
prostheses, 10 with a right-sided unilateral prosthesis), two planning 
strategies were evaluated: i) full exclusion of beams containing 
